TabsDetailsBasic DetailsDate Posted: Wednesday, December 5, 2018Status: CompleteDescription: The aim of this methods project is to make major enhancements to the Active Risk Identification and Analysis (ARIA) tool in order to develop the capability to evaluate the effects of FDA regulatory actions. This will be accomplished by enabling comparisons of outcomes in pre- vs. post-intervention periods. Read More ContributorsWorkgroup Leader(s): Christine Lu, MSc, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MAWorkgroup Member(s): Jolene Damon, MPH; Sandra DeLuccia, MPH; April Duddy, MPH; Jenny Hochstadt, MSc, MSW; Laura Hou, MS, MPH; Joy Kolonoski, MPH; Ella Pestine, MPH; Andrew Petrone, MPH; Rong Chen Tilney, MS; Justin Vigeant; Fang Zhang, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
